Rhythm Pharmaceuticals/$RYTM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Ticker

$RYTM
Sector
Primary listing

Employees

283

RYTM Metrics

BasicAdvanced
$6.5B
-
-$3.02
2.39
-

What the Analysts think about RYTM

Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.

Bulls say / Bears say

Net product revenue from global IMCIVREE sales reached $48.5 million in Q2 2025, a 29% sequential increase from Q1, demonstrating strong commercial momentum (GlobeNewswire)
The pivotal Phase 3 TRANSCEND trial for setmelanotide met its primary endpoint with a placebo-adjusted 19.8% BMI reduction in patients with acquired hypothalamic obesity, supporting expansion into this indication (GlobeNewswire)
The Phase 2 trial of oral MC4R agonist bivamelagon met its primary endpoint with statistically significant, clinically meaningful BMI reductions, potentially extending Rhythm’s MC4R agonist franchise beyond IMCIVREE (GlobeNewswire)
Inventory fluctuations at the specialty pharmacy led to a $7.2 million net decrease in U.S. product revenue in Q1 2025 compared to Q4 2024, highlighting volatility in reported sales (GlobeNewswire)
Rhythm remains highly dependent on IMCIVREE as its sole commercial product, with epidemiology estimates suggesting only ~29,000 U.S. patients for key genetic indications, limiting near-term addressable market growth (SEC Filing)
GAAP net loss per share widened to ($0.75) in Q2 2025, driven by increased R&D and SG&A expenses, underscoring ongoing unprofitability despite revenue gains (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

RYTM Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RYTM Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RYTM

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs